

HHS Public Access

J Thromb Haemost. Author manuscript; available in PMC 2024 April 11.

Published in final edited form as:

Author manuscript

J Thromb Haemost. 2023 April; 21(4): 880–886. doi:10.1016/j.jtha.2022.11.045.

Variability in International Society on Thrombosis and Haemostasis-Scientific and Standardization Committee endorsed Bleeding Assessment Tool (ISTH-BAT) score with normal aging in healthy females: contributory factors and clinical significance

Dearbhla Doherty^{1,2}, Julie Grabell³, Pamela A. Christopherson⁴, Robert R. Montgomery^{4,5}, Barry S. Coller⁶, Michelle Lavin^{1,2}, James S. O'Donnell^{1,2,7}, Paula D. James³, Zimmerman Program Investigators

¹National Coagulation Centre, St James's Hospital, Dublin, Ireland

²Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland

³Department of Medicine, Queen's University, Kingston, Ontario, Canada

⁴Blood Research Institute, Versiti, Milwaukee, WI, USA

⁵Children's Research Institute, Medical College of Wisconsin, Milwaukee, WI, USA

⁶Allen and Frances Adler Laboratory of Blood and Vascular Biology, Rockefeller University, NY, USA

⁷National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Dublin, Ireland

Abstract

Background: Bleeding assessment tools are key screening tests used in the evaluation of patients with suspected inherited bleeding disorders. The International Society on Thrombosis and Haemostasis-Scientific and Standardization Committee endorsed Bleeding Assessment Tool

DECLARATION OF COMPETING INTERESTS

SUPPLEMENTARY MATERIAL

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Correspondence: Dearbhla Doherty, Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin, Ireland. Dearbhladoherty20@rcsi.ie, **TWITTER**: *Dearbhla Doherty* @DearbhDoherty.

AUTHOR CONTRIBUTIONS

D.D. analyzed and interpreted data; J.G. prepared legacy data; P.A.C., R.R.M., B.S.C., and Zimmerman Program Investigators recruited subjects and generated data; J.S.O. and P.D.J. supervised research and analyzed data. All authors (D.D., J.G., P.A.C., R.R.M., B.S.C., M.L., J.S.O., and P.D.J.) were involved in writing and reviewing the manuscript.

D.D. has received educational support funding from Amgen and Novo Norodisk. M.L. acts as a consultant for Sobi, Band Therapeutics and CSL Behring. M.L. has received speaker's fees from CSL Behring and Pfizer and indirect funding for development of educational content from Takeda. J.S.O. has served on the speaker's bureau for Baxter, Bayer, Novo Nordisk, Boehringer Ingelheim, Leo Pharma, Takeda, and Octapharma. He has also served on the advisory boards of Baxter, Bayer, Octapharma CSL Behring, Daiichi Sankyo, Boehringer Ingelheim, Takeda, and Pfizer. J.S.O. has also received research grant funding awards from Baxter, Bayer, Pfizer, Shire, Takeda, and Novo Nordisk. PJ. has research funding from Bayer, and acts as a consultant for Star/Vega Therapeutics and Band Therapeutics. The other authors have no relevant conflicts of interest to declare.

The online version contains supplementary material available at https://doi.org/10.1016/j.jtha.2022.11.045

(ISTH-BAT) has differing reference ranges for adult males (0-3), adult females (0-5), and children (0-2), reflecting differing bleeding symptoms and exposure to hemostatic challenges in these healthy population subgroups. Age is known to markedly impact bleeding score in individuals with von Willebrand disease. However, the influence of age on bleeding score in healthy adult controls is poorly understood.

Objectives: We aimed to assess variability in ISTH-BAT score with age among healthy control females.

Methods: We used the legacy "Merging Project" dataset of normal healthy controls upon which current ISTH-BAT normal ranges are based. We included women, totaling 646 individuals. The normal range (middle 95th percentile) of total ISTH-BAT and grouped subdomain scores between age quartiles was assessed.

Results: The normal range of ISTH-BAT scores increased with age, ranging from 0 to 4 in the youngest quartile (age range, 18–30) to 0 to 6 in the oldest (age range, 52–88). This increased variability with aging was related both to high menorrhagia domain scores in older women and an increase in postprocedural bleeding with accumulated exposure to hemostatic challenges.

Conclusions: Cumulatively, our data highlight that normal aging leads to increased variability in bleeding scores in healthy adult females. Further refinement of the ISTH-BAT with age-adjusted reference ranges may improve the sensitivity and specificity of the tool among females.

Keywords

blood coagulation disorders; inherited; decision support techniques; hemorrhage; menorrhagia; von Willebrand diseases

1 | INTRODUCTION

Identification and quantification of abnormal bleeding is a critical step in the diagnostic pathway of inherited bleeding disorders. Indeed, a bleeding phenotype is a prerequisite for some diagnoses, such as the Bleeding Disorder of Unknown Cause and type 1 von Willebrand disease (VWD) with von Willebrand factor (VWF) levels between 30 and 50 International Units/dL. However, reliably differentiating pathologic mucocutaneous bleeding symptoms from the mild hemorrhagic symptoms seen in the general population remains challenging [1–4]. Over the last 20 years, the development and refinement of standardized Bleeding Assessment Tools (BATs) has sought to address this challenge, beginning with the "Vicenza" score in 2005 [5]. Further iterations, primarily focusing on reducing the time of administration, have since been developed [1,6]: most recently with an International Society on Thrombosis and Haemostasis-Scientific and Standardization Committee endorsed Bleeding Assessment Tool (ISTH-BAT) for use in both adult and pediatric settings [7]. Recent international guidelines advocate the use of standardized BATs in screening for VWD in primary care, with the upper limit of the normal range effectively acting as a medical decision limit to trigger investigation and tertiary referral. In addition, standardized BATs are advised in the tertiary referral setting to assess and document the severity of bleeding symptoms, in conjunction with blood testing as part of the initial diagnostic

workup [8]. ISTH-BAT scores have also been validated in the setting of inherited platelet disorders [9–11].

A normal range for the ISTH-BAT was established in 2014 using the middle 95th percentile of a large population of normal healthy control individuals [12]. Because of the differences in ISTH-BAT distributions between males and females (related to the sex-specific domains of menorrhagia and postpartum hemorrhage), individual reference ranges exist for males (ISTH-BAT; normal range, 0–3) and females (normal range, 0–5). In addition, a pediatric reference range for individuals <18 years was established (0–2), reflecting the limited number of hemostatic challenges encountered by this population [12,13]. More recently, adolescent-appropriate cut-off score values have been proposed [14].

Importantly, however, the accumulation of hemostatic challenges does not plateau at the age of 18. Indeed, aging has been demonstrated to have an impact on BAT scores in patients with VWD, with BAT score increasing by 1.1 unit per decade in females with moderate to severe VWD in the von Willebrand in the Netherlands (WiN) study [15]. Furthermore, the diagnostic accuracy of bleeding scores in VWD has been shown to be age-dependent, even among adult patients, with Tosetto et al. [16] reporting an age-related increase in the performance of two validated bleeding scores among individuals with VWD. In contrast, the impact of aging on BAT scores in a normal healthy population remains poorly defined [12,17].

We sought to evaluate the impact of aging on ISTH-BAT scores in a large healthy control population of women and to assess the effects of increasing age on specific BAT domains.

2 | METHODS

We used the legacy dataset of bleeding scores and demographic data collected from a large cohort of North American healthy control subjects that was used to define the current normal ranges of the ISTH-BAT [12,18]. Demographic data were collected on self-reported age, sex, ethnicity, medical conditions, and medications. Individuals taking regular antiplatelet or anticoagulant medications were excluded from analysis. Owing to the limited numbers of males (n=335) and children (n=328, [169 female, 159 male]) within the cohort, only females 18 years old (n=646) were included.

Individuals were grouped by age quartile (Q1, youngest quartile, to Q4, oldest quartile). ISTH-BAT scores were assessed using total score and sub grouped domain scores as follows: "sex-specific domains score" (sum of the menorrhagia and postpartum hemorrhage [PPH] domains) [12], "challenge domains score" (sum of the surgery and dental extraction domains) [11], and "spontaneous domains score" (sum of all other domains). For clarity, the term "menorrhagia domain" is used to describe the ISTH-BAT domain, whereas the International Federation of Gynecology and Obstetrics (FIGO) recommended term "heavy menstrual bleeding" (HMB) is used in descriptive text [7,19].

Statistical analyses were performed in GraphPad Prism 8.4.3 (GraphPad Software, USA) with a P value <0.05 considered statistically significant. A non-parametric method was used to identify percentile ranking, eg, 97.5th percentile = $(n + 1) \times 0.975$. The normal range was

taken as the 2.5th to 97.5th percentile of normal individuals, as previously reported [12,20]. Fisher exact test was used to test differences in proportions, whereas logistic regression was used to analyze the relationship between independent variables and between quartiles, reported as odds ratio (OR) with 95% CIs.

3 | RESULTS AND DISCUSSION

In this study, 646 females were included, ranging in age from 18 to 88 years old. Age quartile breakdown and demographic data are illustrated in Table 1. For the entire cohort, the normal range for the ISTH-BAT score was 0 to 5, as previously described [12]. However, variability in bleeding scores was observed, with high scores associated with advancing age (Figure 1A, B and Table 1). For example, we observed that subjects in the oldest quartile were approximately three times more likely to have an ISTH-BAT score of 4 when compared with those in the youngest quartile (Q4 vs Q1; OR, 3.12; 95% CI, 1.40–6.74) (Figure 1A, B). Importantly, this age-dependent effect influenced the normal range (middle 95th percentile distribution). In particular, when assessed by age quartiles, the normal ranges were shown to be 0 to 4 (Q1, 18–30 years), 0 to 5 (Q2 and Q3, 31–41 years and 42–51 years, respectively), and 0 to 6 (Q4, 52–88 years) (Table 1). Based on these data, applying the current upper limit of the normal range (0–5) as a cut-off may result in under-referral of younger women with abnormal bleeding. Conversely, older women with bleeding within the normal range (score of 6) may be misclassified as abnormal and consequently undergo unnecessary investigation and management.

We next evaluated the domains within the ISTH-BAT score that led to the increased variability with aging. First, we evaluated the "spontaneous domains score." A similar distribution of spontaneous domains scores was seen between Q1 and Q4 (Figure 1B), with 95% of scores falling within the range between 0 and 3, regardless of age (Table 1). Furthermore, increasing age had no effect on the odds of an individual reporting bleeding in a spontaneous domain (OR, 0.99; 95% CI, 0.98–1.01 for spontaneous domain score >0). This suggests that the increased variability in bleeding scores seen with aging is not due to the accumulation of spontaneous symptoms.

In contrast, age clearly influenced the "sex-specific domains," with an increase in the normal range seen in older women (Q1[0–2] vs Q4 [0–4]) (Table 1 and Figure 1B). Although rates of PPH were numerically higher in the oldest than in the youngest quartile, this was not statistically significant (6.6% vs 3.1%, p = 0.20). In contrast, menorrhagia scores varied markedly with aging, with older women approximately nine times more likely to score 3 in the menorrhagia domain (Q4 vs Q1; OR, 9.18; 95% CI, 2.25–40.52). Management of menorrhagia typically follows a step-wise approach, with medical management prioritized in women who choose to conserve their fertility. Surgical management, in contrast, is typically offered to women who fail, are refractory, or are intolerant of medical treatments [21,22]. Importantly, equal rates of older and younger women sought medical attention for HMB (menorrhagia domain score of 1+, Q1 vs Q4; 27.44% vs 28.14%, p = 0.90), suggesting that the higher menorrhagia domain scores seen in older women are likely due to the accumulation of treatment options with time, rather than increasing prevalence of HMB with aging. Thus, the menorrhagia domain of the ISTH-BAT, although highly sensitive in the

detection of HMB in women with bleeding disorders [23], appears to be implicitly weighted toward older women, even among healthy controls.

Challenge domains were also impacted by age. Although the upper limit of the normal range for postchallenge bleeding was 0 in the youngest age quartile, this increased to 3 in the oldest quartile (Table 1, Figure 1B). Indeed, the odds of reporting a history of postchallenge bleeding increased by 3.3% per year of age (OR, 1.03; 95% CI, 1.003–1.06). Rates of surgical and dental challenges significantly increased with age, with individuals in the oldest quartile 3.8 and 2.6 times more likely to have undergone surgery (Q4 vs Q1; OR, 3.8; 95% CI, 2.30–6.34) and dental extraction, (Q4 vs Q1; OR, 2.6; 95% CI, 1.59–4.42), respectively, when compared with those in the youngest quartile.

Interestingly, there was no increased likelihood of postchallenge bleeding in individuals with a history of spontaneous bleeding (OR, 1.647; 95% CI, 0.6039–4.166). In addition, no individual reported a history of bleeding after both dental extraction and surgery. This suggests, as expected in a control population with no known bleeding disorders, that post challenge bleeding occurs because of local or surgical factors, independent of the bleeding history. Thus, our data suggest that the increased variability in bleeding scores seen with aging is in part due to the procedure-specific accumulation of post challenge bleeding as more individuals are exposed to procedures (Figure 2).

Our study has a number of limitations. In the preliminary analysis, we observed a similar increase in rates of surgical and dental challenges with age among healthy control males. However, our dataset was underpowered to evaluate whether a corresponding broadening of bleeding score was also present with aging in males. Owing to the narrow reference range and without the impact of age-associated variation in the menorrhagia domain seen in females, we hypothesize that any age-related effects on ISTH-BAT scores in males is likely to be more subtle and will require large adequately powered cohorts to be detected. Furthermore, although our dataset included women up to the age of 88, only 6% (40/646) of the cohort were above 65 years of age. Further dedicated studies evaluating an older population may reveal an even higher spread of bleeding scores in older healthy females. Finally, as we only included females aged 18 years in our analysis, the critical issue of adolescent-specific normal ranges remains to be addressed.

Our data provide the first comprehensive study on the variability of bleeding scores with normal aging and the assessment of factors that drive this variability. Using the large dataset of healthy control individuals upon which the current ISTH-BAT female reference range is based further strengthens our study.

4 | CONCLUSION

Cumulatively, our data suggest that normal aging leads to increased variability in bleeding scores among healthy women, related both to step-wise increases in the menorrhagia domain scores among women with HMB and the accrual of postprocedural bleeding with increasing exposure to procedures (Figure 2). We anticipate that if our data are validated by others, further refinement of the ISTH-BAT with age-adjusted reference ranges may improve its

sensitivity as a diagnostic tool in younger women, while enhancing specificity in older women. Further studies are required to address the outstanding critical issue of the ISTH-BAT normal range in adolescents and to investigate for the presence of any effect of aging on the distribution of bleeding scores in males.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

This work was performed within the Irish Clinical Academic Training Program, supported by the Wellcome Trust and the Health Research Board (Grant Number 203930/B/16/Z), the Health Service Executive, National Doctors Training and Planning and the Health and Social Care Research and Development Division, Northern Ireland. The study was also supported by funds from the NIH for the Zimmerman Program (HL081588) and the National Center For Advancing Translational Science (UL1 TR001866) Clinical and Translational Science Award Program, and a Science Foundation Ireland Principal Frontiers for the Future (FFP) award (20/FFP-A/8952).

REFERENCES

- [1]. Kalot MA, Husainat N, Tayiem S, Alayli AE, Dimassi AB, Diab O, Abughanimeh O, Madoukh B, Qureini A, Ameer B, Paola JD, Eikenboom JCJ, Jacobs-Pratt V, McLintock C, Montgomery R, O'Donnell JS, Sidonio R Jr, Brignardello-Petersen R, Flood V, Connell NT, et al. Bleeding assessment tools in the diagnosis of von willebrand disease in adults and children: a systematic review and meta-analysis of test accuracy. Blood Adv. 2021;5:5023–31. [PubMed: 34597385]
- [2]. Kalot MA, Al-Khatib M, Connell NT, Flood V, Brignardello-Petersen R, James P, Mustafa RA, VWD working group. An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia. 2020;26:106–16. [PubMed: 31769905]
- [3]. Rodeghiero F, Pabinger I, Ragni M, Abdul-Kadir R, Berntorp E, Blanchette V, Bodó I Casini A, Gresele P, Lassila R, Leebeek F, Lillicrap D, Mezzano D, Noris P, Srivastava A, Tosetto A, Windyga J, Zieger B, Makris M, Key N. Fundamentals for a systematic approach to mild and moderate inherited bleeding disorders: an EHA consensus report. Hemasphere. 2019;3:e286. [PubMed: 31942541]
- [4]. van Galen K, Lavin M, Skouw-Rasmussen N, Fischer K, Noone D, Pollard D, Mauser-Bunschoten E, Khair K, Gomez K, van Loon E, Bagot CN, Elfvinge P, d'Oiron R, Abdul-Kadir R. European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD). European principles of care for women and girls with inherited bleeding disorders. Haemophilia. 2021;27:837–47. [PubMed: 34343384]
- [5]. Rodeghiero F, Castaman G, Tosetto A, Batlle J, Baudo F, Cappelletti A, Casana P, De Bosch N, Eikenboom JC, Federici AB, Lethagen S, Linari S, Srivastava A. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost. 2005;3:2619–26. [PubMed: 16359502]
- [6]. Rydz N, James PD. The evolution and value of bleeding assessment tools. J Thromb Haemost. 2012;10:2223–9. [PubMed: 22974079]
- [7]. Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, Neunert C, Lillicrap D. ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8:2063–5. [PubMed: 20626619]
- [8]. James PD, Connell NT, Ameer B, Di Paola J, Eikenboom J, Giraud N, Haberichter S, Jacobs-Pratt V, Konkle B, McLintock C, McRae S, Montgomery R, O'Donnell JS, Scappe N, Sidonio R, Flood VH, Husainat N, Kalot MA, Mustafa RA. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5:280–300. [PubMed: 33570651]

- [9]. Adler M, Kaufmann J, Alberio L, Nagler M. Diagnostic utility of the ISTH bleeding assessment tool in patients with suspected platelet function disorders. J Thromb Haemost. 2019;17:1104– 1112. [PubMed: 31021046]
- [10]. Gresele P, Orsini S, Noris P, Falcinelli E, Alessi MC, Bury L, Borhany M, Santoro C, Glembotsky AC, Cid AR, Tosetto A, De Candia E, Fontana P, Guglielmini G, Pecci A, BAT-VAL study investigators. Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: a communication from the Platelet Physiology SSC. J Thromb Haemost. 2020;18:732– 739. [PubMed: 31750621]
- [11]. Lowe GC, Lordkipanidzé M, Watson SP, UK GAPP study group. Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders. J Thromb Haemost. 2013;11:1663–8. [PubMed: 23809206]
- [12]. Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, Hopman W, Clark DS, Mauer AC, Bowman M, Riddel J, Christopherson PA, Montgomery RR, Zimmerman Program Investigators, Rand ML, Coller B, James PD. Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project. Haemophilia. 2014;20:831–5. [PubMed: 25196510]
- [13]. Bidlingmaier C, Grote V, Budde U, Olivieri M, Kurnik K. Prospective evaluation of a pediatric bleeding questionnaire and the ISTH bleeding assessment tool in children and parents in routine clinical practice. J Thromb Haemost. 2012;10:1335–41. [PubMed: 22578063]
- [14]. Jain S, Zhang S, Acosta M, Malone K, Kouides P, Zia A. Prospective evaluation of ISTH-BAT as a predictor of bleeding disorder in adolescents presenting with heavy menstrual bleeding in a multidisciplinary hematology clinic. J Thromb Haemost. 2020;18:2542–50. [PubMed: 32654321]
- [15]. de Wee EM, Sanders YV, Mauser-Bunschoten EP, van der Bom JG, Degenaar-Dujardin ME, Eikenboom J, de Goede-Bolder A, Laros-van Gorkom BA, Meijer K, Hamulyák K, Nijziel MR, Fijnvandraat K, Leebeek FW. WiN study group. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost. 2012;108:683–92. [PubMed: 22918553]
- [16]. Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Lethagen S, Hill FG, Peake I. A comparison between two semi-quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease. Haemophilia. 2011;17:165–6. [PubMed: 21199188]
- [17]. Mauer AC, Khazanov NA, Levenkova N, Tian S, Barbour EM, Khalida C, Tobin JN, Coller BS. Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults. J Thromb Haemost. 2011;9:100–8. [PubMed: 20942847]
- [18]. Spradbrow J, Letourneau S, Grabell J, Liang Y, Riddel J, Hopman W, Blanchette VS, Rand ML, Coller BS, Paterson AD, James PD. Bleeding assessment tools to predict von Willebrand disease: utility of individual bleeding symptoms. Res Pract Thromb Haemost. 2020;4:92–9. [PubMed: 31989089]
- [19]. Fraser IS, Critchley HO, Broder M, Munro MG. The FIGO recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med. 2011;29:383–90. [PubMed: 22065325]
- [20]. Bowman M, Mundell G, Grabell J, Hopman WM, Rapson D, Lillicrap D, James P. Generation and validation of the condensed MCMDM-1VWD bleeding questionnaire for von Willebrand disease. J Thromb Haemost. 2008;6:2062–6. [PubMed: 18983516]
- [21]. Oehler MK, Rees MCP. Menorrhagia: an update. Acta Obstet Gynecol Scand. 2003;82:405–22.[PubMed: 12752071]
- [22]. National Institute for Health and Care Excellence. Heavy menstrual bleeding: assessment and management. https://www.nice.org.uk/guidance/ng88/evidence: NICE guideline [NG88]; 2018. Accessed September 27, 2022.
- [23]. Lavin M, Aguila S, Dalton N, Nolan M, Byrne M, Ryan K, White B, O'Connell NM, O'Sullivan JM, Di Paola J, James PD, O'Donnell JS. Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Adv. 2018;2:1784–91. [PubMed: 30042144]

Essentials:

- Bleeding scores, such as the International Society on Thrombosis and Haemostasis-Scientific and Standardization Committee endorsed Bleeding Assessment Tool (ISTH-BAT), are used in the investigation of bleeding disorders.
- Different normal ranges of the ISTH-BAT currently exist for males, females, and children.
- Our data highlight that ISTH-BAT normal ranges vary with age in adult female healthy controls.
- This is because of higher menorrhagia scores and accrual of post challenge bleeding in older women.




FIGURE 1.

(A) ISTH-BAT score by age quartile among females (Quartile 1-Quartile 4), with each point representing the total ISTH-BAT score of a healthy control individual. Distribution of ISTH-BAT scores changed with normal aging; subjects in the oldest quartile (Q4) were approximately 3 times more likely to have an ISTH-BAT score of 4, when compared with those in the youngest quartile (Q1), (Q4 vs Q1; 13.77% vs 4.88%; odds ratio, 3.12; 95% CI, 1.40–6.74). (B) Heat-map visualization illustrating total ISTH-BAT and sub group domain scores (rows) reported by each subject (columns) in the youngest (Q1) and oldest quartile (Q4). Increasing scores are illustrated by color change, from green (score of 0) to red (score of 6), as shown in color key. Individuals in both quartiles had similar distribution of Spontaneous domains scores. In contrast, the distribution of sex-specific domains scores (sum of the Menorrhagia and PPH domains) and challenge domains scores (sum of the Surgery and Dental Extraction domains) broadened with age. Only subjects with ISTH-BAT

1 are included for illustrative purposes. ISTH-BAT, International Society on Thrombosis and Haemostasis-Scientific and Standardization Committee endorsed Bleeding Assessment Tool; PPH, postpartum hemorrhage




FIGURE 2.

Illustrative representation of variability in ISTH-BAT score with normal aging, Increasing scores are illustrated by color change, from green (score of 0) to red (score of 6), as shown in color key. HMB, heavy menstrual bleeding; ISTH-BAT, International Society on Thrombosis and Haemostasis-Scientific and Standardization Committee endorsed Bleeding Assessment Tool

-
_
<u> </u>
—
_
_
\sim
\mathbf{O}
-
<
\leq
\leq
≤a
R
2
R
JUC
nut
JUC
anus
nut
anusc
anuscr
anusc
anuscr
anuscri
anuscri

TABLE 1

Demographic data and ISTH-BAT data in total female cohort and by age quartile.

	Total	QI	Q2	Q3	Q4
Demographic data					
п	646	164	165	150	167
Age, y	41 (18–88)	25 (18–30)	36 (31–41)	46 (42–51)	59 (52–88)
Median (range)					
Ethnicity, n (%) 3	n = 634	n = 161	n = 164	n = 146	n = 163
African American	86 (13.6%)	23 (14.3%)	28 (17.1%)	27 (18.5%)	8 (4.9%)
Asian	31 (4.9%)	10 (6.2%)	10 (6.1%)	9 (6.2%)	2 (1.2%)
Other b	7 (1.1%)	3 (1.9%)	3 (1.8%)	1 (0.7%)	0 (0%)
White	510 (80.4%)	125 (77.6%)	123 (75.0%)	109 (74.7%)	153 (93.9%)
ISTH-BAT data					
Overall ISTH-BAT score 2.5th-97.5th percentile	0-5	0-4	0-5	0-5	90
Spontaneous domains score 2.5th-97.5th percentile	0–3	0–3	0–3	0–3	0–3
Sex-specific domains score 2.5th-97.5th percentile	0-4	0–2	0-4	0-4	0-4
Challenge domains score 2.5th-97.5th percentile	0-2	0-0	0-2	0-2	0^{-3}

Tool. Sex-specific domains score (menorrhagia and postpartum hemorrhage [PPH] domains), challenge domains score (surgery and dental extraction domains) and spontaneous domains score (all other domains).

 $^{2}\mathrm{Denominator}$ is number of individuals with ethnicity data reported.

 b Other, including American Indian, Pacific Islander and multiracial.